11d Relevant concomitant care and interventions that are permitted or prohibited during the trial N/A Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 8-9
Participant timeline 13 Time schedule of enrolment, interventions (including any runins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 9-10, Table  2 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 10 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (eg, computergenerated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 
